Distribution and Absence of Generalized Lesions in Mice Following Single Dose Intramuscular Inoculation of the Vaccine Candidate MVA-MERS-S

Overview

Journal Biologicals

Specialties Allergy & Immunology
Biotechnology

Date 2018 May 16

PMID 29759890

Citations 11

Authors

Martin C Langenmayer

Anna-Theresa Lulf-Averhoff

Silvia Adam-Neumair

Robert Fux

Gerd Sutter

Asisa Volz

Affiliations

Soon will be listed here.

Abstract

Modified Vaccinia Virus Ankara (MVA) is a highly attenuated and replication-deficient virus serving as vaccine against infectious diseases. Here, we assessed the in vivo distribution of a recombinant MVA candidate vaccine against the Middle Eastern Respiratory Syndrome (MVA-MERS-S) in mice. Intramuscularly inoculated mice were necropsied at different time points and examined by histology, immunohistochemistry and real-time PCR. We detected inflammation and myonecrosis at the parenteral site and hyperplasia of the draining lymph nodes. MVA-MERS-S did not result in detectable lesions in tissues peripheral to the parenteral site and draining lymph nodes. Real-time PCR analysis of >240 tissue samples detected MVA-DNA predominantly at the injection site and in the draining lymph nodes, and suggested continuous clearance of the candidate vaccine during the observation period. Levels of parenteral site inflammation and hyperplasia of draining lymph nodes were considered in line with immunological responses to vaccine inoculation.

Citing Articles

Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice.

Langenmayer M, Luelf-Averhoff A, Marr L, Jany S, Freudenstein A, Adam-Neumair S Pathogens. 2023; 12(7).

PMID: 37513714 PMC: 10383309. DOI: 10.3390/pathogens12070867.

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.

Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y Signal Transduct Target Ther. 2023; 8(1):149.

PMID: 37029123 PMC: 10081433. DOI: 10.1038/s41392-023-01408-5.

Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the and families (Review).

Babaeimarzangou S, Zaker H, Soleimannezhadbari E, Gamchi N, Kazeminia M, Tarighi S Exp Ther Med. 2022; 25(1):42.

PMID: 36569444 PMC: 9768462. DOI: 10.3892/etm.2022.11741.

Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein.

Kupke A, Volz A, Dietzel E, Freudenstein A, Schmidt J, Shams-Eldin H Vaccines (Basel). 2022; 10(4).

PMID: 35455282 PMC: 9027530. DOI: 10.3390/vaccines10040533.

Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies.

Choi J, Kim J J Microbiol. 2022; 60(3):238-246.

PMID: 35089585 PMC: 8795722. DOI: 10.1007/s12275-022-1547-8.

References

Sutter G, Moss B . Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A. 1992; 89(22):10847-51. PMC: 50439. DOI: 10.1073/pnas.89.22.10847. View

Schroeder K, Nitsche A . Multicolour, multiplex real-time PCR assay for the detection of human-pathogenic poxviruses. Mol Cell Probes. 2009; 24(2):110-3. DOI: 10.1016/j.mcp.2009.10.008. View

Sanchez-Sampedro L, Perdiguero B, Mejias-Perez E, Garcia-Arriaza J, Di Pilato M, Esteban M . The evolution of poxvirus vaccines. Viruses. 2015; 7(4):1726-803. PMC: 4411676. DOI: 10.3390/v7041726. View

Volz A, Sutter G . Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development. Adv Virus Res. 2017; 97:187-243. PMC: 7112317. DOI: 10.1016/bs.aivir.2016.07.001. View

Hanke T, McMichael A, Dennis M, Sharpe S, Powell L, McLoughlin L . Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine. 2005; 23(12):1507-14. DOI: 10.1016/j.vaccine.2004.08.050. View

Haagmans B, van den Brand J, Raj V, Volz A, Wohlsein P, Smits S . An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2015; 351(6268):77-81. DOI: 10.1126/science.aad1283. View

Ondondo B, Brennan C, Nicosia A, Crome S, Hanke T . Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice. Vaccine. 2013; 31(47):5594-601. PMC: 3898262. DOI: 10.1016/j.vaccine.2013.06.068. View

Hanke T, McMichael A, Samuel R, Powell L, McLoughlin L, Crome S . Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine. 2002; 21(1-2):108-14. DOI: 10.1016/s0264-410x(02)00403-6. View

Stittelaar K, Kuiken T, de Swart R, van Amerongen G, Vos H, Niesters H . Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine. 2001; 19(27):3700-9. DOI: 10.1016/s0264-410x(01)00075-5. View

10.

Volz A, Langenmayer M, Jany S, Kalinke U, Sutter G . Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara. J Virol. 2014; 88(18):10946-57. PMC: 4178859. DOI: 10.1128/JVI.00945-14. View

11.

Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H . Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. J Virol. 2015; 89(16):8651-6. PMC: 4524222. DOI: 10.1128/JVI.00614-15. View

12.

Lulf A, Freudenstein A, Marr L, Sutter G, Volz A . Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes. Virology. 2016; 499:322-330. PMC: 7111619. DOI: 10.1016/j.virol.2016.09.006. View

13.

Verheust C, Goossens M, Pauwels K, Breyer D . Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine. 2012; 30(16):2623-32. DOI: 10.1016/j.vaccine.2012.02.016. View